Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Breast Cancer Test will Help More Women Avoid Unnecessary Chemotherapy

Published: Friday, July 05, 2013
Last Updated: Friday, July 05, 2013
Bookmark and Share
A new genetic test will help doctors better identify those women who should be considered for chemotherapy, and those who can avoid it.

A team at The Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust and Queen Mary University of London found that the test - called PAM50 - produced better long-term information than current methods for determining if a patient’s breast cancer would return.

The test, which can be processed locally instead of being sent off to an American lab, indentifies more women with the highest risk of their breast cancer returning, with fewer women classed as at intermediate risk.

The new test could therefore help doctors identify with greater certainty the women who will have the most potential of benefitting from chemotherapy, while letting others avoid unnecessary treatment.

The research, published today (Monday) in the Journal of Clinical Oncology, was funded by Breakthrough Breast Cancer, AstraZeneca and the NIHR Biomedical Research Centre at The Royal Marsden, with additional support from Cancer Research UK.

Breast cancer is diagnosed in 50,000 women every year, with 80% of cases caused by oestrogen receptor positive (ER+) disease. Women with this type of breast cancer can be treated with hormone therapy, but for some women, the risk of their breast cancer coming back within 10 years means they are also given chemotherapy.

Currently, a test called Oncotype DX (1) can assess the likelihood of a patient’s breast cancer returning, but the test costs more than £2,000 per patient to be administered privately and samples must be sent abroad to be processed. The current test also identifies a large portion of women as having ‘intermediate risk’, making a doctor’s decision of whether chemotherapy will help more difficult.

In this study, scientists assessed RNA in tissue samples taken from 940 patients with ER+ breast cancer and compared the new PAM50 score, which analyses 50 genes linked with breast cancer, with the Oncotype DX test, and with a test called IHC4, developed by Breakthrough Breast Cancer.

The PAM50 test provided more long-term predictive information for doctors than both the Oncotype DX test and IHC4, while being as effective as other tests in identifying women at low risk of their breast cancer recurring.

Notably, the PAM50 test categorised more patients as having a high risk of their breast cancer returning within 10 years and fewer as intermediate than the other two tests. The researchers said the PAM50 test could therefore be a more cost-effective tool while providing doctors with more relevant information for determining which breast cancer patients will benefit most from chemotherapy.

Professor Mitch Dowsett, Professor of Biochemical Endocrinology at The Institute of Cancer Research and Head of Biochemistry at The Royal Marsden, said: “Chemotherapy is often used after surgery to reduce the risk of a patient’s breast cancer coming back, but the side-effects are significant and some women will not see any benefit. While the current test is useful for both patients and clinicians to help them decide whether chemotherapy is needed, it’s expensive and not available locally.

“Our study found that the PAM50 test is more effective than other methods at providing the information to exclude breast cancer patients from unnecessary chemotherapy, and has the potential to be done more quickly. For each sub-group of breast cancer the PAM50 test added significant information beyond that of the standard clinical treatment score and the Oncotype DX score combined.”

Professor Alan Ashworth, Chief Executive of The Institute of Cancer Research, said: “The great strides that have been made in breast cancer treatment have resulted in a large rise in survival from the disease, but some women receive treatment which can be arduous while receiving no benefit. This test will improve doctors’ knowledge of who might benefit, allowing more women to make better informed decisions on their treatment.”

Breakthrough Breast Cancer’s Director of Research Julia Wilson said: “The PAM50 test has been proven to be an effective way of helping clinicians ensure that women do not have to undergo chemotherapy treatment that will not have any medical benefit, when their risk of cancer recurrence is in fact very low. This will mean that, where appropriate, women will be able to avoid the toxic side effects of chemotherapy.

“We’re aiming to reach a stage where all breast cancer patients receive the  most appropriate treatment for them, and this research from Mitch and his team is an important step in that direction.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Detecting Aggressive and Treatment-Resistant Cancers
Scientists have developed a new imaging test that could enable doctors to identify more dangerous tumours before they spread around the body – and tailor treatment accordingly.
Monday, December 14, 2015
Major Study Links Gene to Drug Resistance in Testicular Cancer
Researchers used a genetic technique called whole-exome sequencing to examine tumour samples.
Friday, January 23, 2015
Nuevolution Enter Drug Discovery Collaboration with ICR and CRT
International deal to screen potential cancer drugs using DNA ‘barcodes’.
Thursday, January 23, 2014
Study of 'Sister' Stem Cells Uncovers New Cancer Clue
Scientists have used a brand new technique for examining individual stem cells to uncover dramatic differences in the gene expression levels between apparently identical ‘sister’ pairs.
Monday, September 30, 2013
Researchers Say Studying the Caterpillar May Help us Understand Cancer
How researchers are beginning to exploit the mysterious phenomenon of epigenetics.
Friday, July 05, 2013
Next-Generation “Epigenetic” Cancer Pill Shown to be Safe
Scientists have shown that a brand new type of cancer pill that exploits the emerging field of epigenetics is safe for human use, according to a Phase I trial reported today in Clinical Cancer Research.
Wednesday, May 02, 2012
Scientific News
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
NCI Collaborates with Multiple Myeloma Research Foundation
NCI collaborates with MMRF to incorporate genomic and clinical data into NCI Genomic Data Commons database.
Epigenetic Clock Predicts Life Expectancy
New research finds 5 percent of population ages faster, faces shorter lifespan.
Modified Yeast Shows Plant Response to Key Hormone
Researchers have developed a toolkit based on modified yeast to determine plant responses to auxin.
Death-or-Repair Switch Protein Identified
Researchers have identified a protein that plays a key role in the decision process of cell damage repair or cellular suicide.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Regulatory RNA Essential to DNA Damage Response
Researchers discover a tumour suppressor is stabilized by an RNA molecule, which helps cells respond to DNA damage.
Wearable Microscope Can Measure Fluorescent Dyes Through Skin
UCLA research could make monitoring disease biomarkers easier and more cost-effective.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Genetic Impact of Endurance Training
Research has found that endurance training changes genetic activity in thousands of genes, giving rise to large number of altered RNA variants.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!